Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 6;24(5):5041.
doi: 10.3390/ijms24055041.

Ovarian Cancer and Glutamine Metabolism

Zacharias Fasoulakis  1 , Antonios Koutras  1 , Thomas Ntounis  1 , Ioannis Prokopakis  1 , Paraskevas Perros  1 , Athanasios Chionis  2 , Ioakeim Sapantzoglou  1 , Alexandros Katrachouras  3 , Kyriakos Konis  4 , Athina A Samara  5 , Asimina Valsamaki  6 , Vasileios-Chrysovalantis Palios  7 , Panagiotis Symeonidis  8 , Konstantinos Nikolettos  9 , Athanasios Pagkalos  10 , Sotirios Sotiriou  11 , Marianna Theodora  1 , Panos Antsaklis  1 , Georgios Daskalakis  1 , Emmanuel N Kontomanolis  9
Affiliations
Review

Ovarian Cancer and Glutamine Metabolism

Zacharias Fasoulakis et al. Int J Mol Sci. .

Abstract

Cancer cells are known to have a distinct metabolic profile and to exhibit significant changes in a variety of metabolic mechanisms compared to normal cells, particularly glycolysis and glutaminolysis, in order to cover their increased energy requirements. There is mounting evidence that there is a link between glutamine metabolism and the proliferation of cancer cells, demonstrating that glutamine metabolism is a vital mechanism for all cellular processes, including the development of cancer. Detailed knowledge regarding its degree of engagement in numerous biological processes across distinct cancer types is still lacking, despite the fact that such knowledge is necessary for comprehending the differentiating characteristics of many forms of cancer. This review aims to examine data on glutamine metabolism and ovarian cancer and identify possible therapeutic targets for ovarian cancer treatment.

Keywords: cancer cell; cancer treatment; glutamine; metabolism; ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. Cancer J. Clin. 2014;64:9–29. doi: 10.3322/caac.21208. - DOI - PubMed
    1. Mirandola L., Cannon J.M., Cobos E., Bernardini G., Jenkins M.R., Kast W.M., Chiriva-Internati M. Cancer testis antigens: Novel biomarkers and targetable proteins for ovarian cancer. Int. Rev. Immunol. 2011;30:127–137. doi: 10.3109/08830185.2011.572504. - DOI - PubMed
    1. Rooth C. Ovarian cancer: Risk factors, treatment and management. Br. J. Nurs. 2013;22((Suppl. 17)):S23–S30. doi: 10.12968/bjon.2013.22.Sup17.S23. - DOI - PubMed
    1. Sung P.L., Chang Y.H., Chao K.C., Chuang C.M. Global distribution pattern of histological subtypes of epithelial ovarian cancer: A database analysis and systematic review. Gynecol. Oncol. 2014;133:147–154. doi: 10.1016/j.ygyno.2014.02.016. - DOI - PubMed
    1. Kajiyama H., Shibata K., Mizuno M., Umezu T., Suzuki S., Yamamoto E., Fujiwara S., Kawai M., Nagasaka T., Kikkawa F. Long-term clinical outcome of patients with recurrent epithelial ovarian carcinoma: Is it the same for each histological type? Int. J. Gynecol. Cancer. 2012;22:394–399. doi: 10.1097/IGC.0b013e31823eed2c. - DOI - PubMed